Iron status and inflammation in early stages of chronic kidney disease

Kidney and Blood Pressure Research

Volumn 40, Issue 4, 2015, Pages 366-373

  Łukaszyk, Ewelina ^a   Łukaszyk, Mateusz ^a   Koc Zórawska, Ewa ^a   Tobolczyk, Jolanta ^a   Bodzenta ŁUkaszyk, Anna ^a   Małyszko, Jolanta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic kidney disease; Hepcidin; Inflammation; Iron

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FERRITIN; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HEMOJUVELIN; HEPCIDIN; HEPCIDIN 25; INTERLEUKIN 6; IRON; PROTEIN; PROTHROMBIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UREA; URIC ACID; ZONULIN; BIOLOGICAL MARKER; NONHEME IRON PROTEIN;

ADULT; AGE; ARTICLE; BLOOD CELL COUNT; BODY MASS; CHEMICAL PARAMETERS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC KIT; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON METABOLISM; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; TRANSFERRIN BLOOD LEVEL; TRANSFERRIN SATURATION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGED; AGING; CHRONIC KIDNEY FAILURE; DEFICIENCY; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; NUTRITIONAL STATUS; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; BIOMARKERS; BLOOD CELL COUNT; FEMALE; HUMANS; INFLAMMATION; IRON; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NONHEME IRON PROTEINS; NUTRITIONAL STATUS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84936966567     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368512     Document Type: Article

References (38)

1. Murray MJ, Murray AB, Murray MB, Murray CJ: The adverse effect of iron repletion on the course of certain infections. Br Med J 1978;2:1113-1115.
2. Prentice AM: Iron metabolism, malaria and other infections: what is all the fuss about? J Nutr 2008;138:2537-2541.
3. Hansen JB, Moen IW, Mandrup-Poulsen T: Iron: the hard player in diabetes pathophysiology. Acta Physiol 2014;210:717-732.
4. Wallace DF, Subramaniam VN: Co-factors in liver disease: the role of HFE hereditary hemochromatosis and iron. Biochim Biophys Acta 2009;1790:663-667.
5. Toyokuni S: Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
6. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P: Iron deficiency: an ominous sign in patients with systolic heart failure. Eur Heart J 2010;31:1872-1880.
7. Wish JB: Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:S4-S8.
8. Park C, Valore E, Waring A, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
9. Nicolas G, Chauvet C, Viattel L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
10. Nemeth E, Valore E, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 2003;101:2461-2463.
11. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1-150.
12. Malyszko J, Koc-Zórawska E, Levin-Iaina N, Małyszko J, Koźmiński P, Kobus G, Mys̈liwiec M: New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol Arch Med Wewn 2012;122:537-542.
13. Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; NephroTest Study Group: The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease. PLoS One 2014;30:e99781.
14. Lin L, Goldberg YP, Ganz T: Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005;106:2884-2889.
15. Malyszko J, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Kozminski P, Mysliwiec M: Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients? Int Urol Nephrol 2012;44:1805-1811.
16. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T, Zhang HP, Marquis CP, Jiang L, Lockwood G, Lee-Ng M, Husaini Y, Wu L, Hamilton JA, Brown DA: The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011;29:187-195.
17. Eggers KM, Kempf T, Lind L, Sundström J, Wallentin L, Wollert KC, Siegbahn A: Relations of growthdifferentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 2012;72:45-51.
18. World Health Organization: Nutritional anemias: Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1968;405:5-37.
19. Malyszko J, Koc-Zorawska E, Malyszko JS, Glowinska I, Mysliwiec M, Macdougall IC: GDF15 is related to anemia and hepcidin in kidney allograft recipients. Nephron Clin Pract 2013;123:112-117.
20. Ho JE, Hwang SJ, Wollert KC, Larson MG, Cheng S, Kempf T, Vasan RS, Januzzi JL, Wang TJ, Fox CS: Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem 2013;59:1613-1620.
21. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251-1253.
22. Shu T, Jing C, Lv Z, Xie Y, Xu J, Wu J: Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol 2015;94:67-73.
23. Nakagawa H, Tamura T, Mitsuda Y, Goto Y, Kamiya Y, Kondo T, Wakai K, Hamajima N: Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study. BMC Hematol 2014;14:6.
24. Przybyszewska J, Zekanowska E, Kędziora-Kornatowska K, Boinska J, Cichon R, Porzych K: Serum prohepcidin and other iron metabolism parameters in elderly patients with anemia of chronic disease and with iron deficiency anemia. Pol Arch Med Wewn 2013;123:105-111.
25. Cook JD, Skikne BS, Baynes RD: Serum Transferrin Receptor. Annu Rev Med 1993;44:63-74.
26. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD: Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 1992;119:385-390.
27. Braga F, Infusino I, Dolci A, Panteghini M: Soluble transferrin receptor in complicated anemia. Clin Chim Acta 2014;431:143-147.
28. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD: Serum transferrin receptor distinguishes the anemia of chronic disease from IDA. J Lab Clin Med 1992;119:385-390.
29. Cazzola M, Ponchio L, de Benedeti F, Ravelli A, Rosti V, Beguin Y, Invernizzi R, Barosi G, Martini A: Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824-4830.
30. Berlin T, Meyer A, Rotman-Pikielny P, Natur A, Levy Y: Soluble Transferrin Receptor as a Diagnostic Laboratory Test for Detection of Iron Deficiency Anemia in Hospitalized Patients with Acute Illness. IMAJ 2011:13:96-98.
31. Fasano A: Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. Physiol Rev 2011;91:151-175.
32. Klaus DA, Motal MC, Burger-Klepp U, Marschalek C, Schmidt EM, Lebherz-Eichinger D, Krenn CG, Roth GA: Increased plasma zonulin in patients with sepsis. Biochem Med 2013;23:107-111.
33. Malyszko J, Koc-Zorawska E, Levin-Iaina N, Malyszko J: Zonulin, iron status and anemia in kidney transplant recipients; are they related? Transplant Proc 2014;46:2644-2646.
34. Przybylowski P, Nowak E, Janik L, Wasilewski G, Malyszko J: Zonulin and iron metabolism in heart transplant recipients. Transplant Proc 2014;46:2856-2859.
35. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L: Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res 2013;37:305-310.
36. Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M: Twice-monthly administration of a lower dose of epoetin Beta pegol can maintain adequate hemoglobin levels in hemodialysis patients. Ther Apher Dial 2015;19:138-143.
37. Choi JY, Yang CW, Kim YH, Joo KW, Yoo TH, Lee KW, Lee SH, Moon JY, Shin SK,Huh W, Kim NH, Park SH, Kim CD, Kim YL: Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients. Kidney Blood Press Res 2013;37:259-268.
38. Gade K, Blaschke S, Rodenbeck A, Becker A, Anderson-Schmidt H, Cohrs S: Uremic restless legs syndrome (RLS) and sleep quality in patients with end-stage renal disease on hemodialysis: potential role of homocysteine and parathyroid hormone. Kidney Blood Press Res 2013;37:458-463.